Baillie Gifford & Co. Grows Holdings in BioNTech SE (NASDAQ:BNTX)

Baillie Gifford & Co. grew its holdings in BioNTech SE (NASDAQ:BNTX) by 0.4% during the third quarter, HoldingsChannel.com reports. The firm owned 8,308,071 shares of the company’s stock after acquiring an additional 31,773 shares during the quarter. Baillie Gifford & Co.’s holdings in BioNTech were worth $986,750,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GSA Capital Partners LLP purchased a new stake in BioNTech in the third quarter worth $373,000. Arlington Capital Management Inc. increased its stake in BioNTech by 46.4% in the third quarter. Arlington Capital Management Inc. now owns 3,807 shares of the company’s stock worth $452,000 after purchasing an additional 1,207 shares during the period. Lodestone Wealth Management LLC purchased a new stake in BioNTech in the third quarter worth $8,373,000. Caas Capital Management LP increased its stake in BioNTech by 145.4% in the third quarter. Caas Capital Management LP now owns 17,190 shares of the company’s stock worth $2,042,000 after purchasing an additional 10,185 shares during the period. Finally, New York State Common Retirement Fund increased its stake in BioNTech by 457.9% in the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $108.73 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.33. The company has a market cap of $25.85 billion, a PE ratio of -51.78 and a beta of 0.26. The business has a 50-day simple moving average of $112.26 and a two-hundred day simple moving average of $96.82. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the company earned $0.73 earnings per share. As a group, equities analysts expect that BioNTech SE will post -3.47 EPS for the current fiscal year.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent analyst reports. TD Cowen reduced their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. HSBC raised their price target on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Bank of America raised their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. HC Wainwright raised their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $137.54.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.